To explore whether the H3K9 acetylation modification of TLR9 gene was a consequence of immune regulation activation during application of the combination therapy, we first evaluated the expression levels of IL-6, IL-12, IFN-γ, and TNF-α in the serum of healthy volunteers, patients with hepatitis B, and patients treated with the combination therapy. The gene discussed is IFNG; the disease is hepatitis B virus infection.